These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19398128)

  • 1. p53 autoantibodies, cytokine levels and ovarian carcinogenesis.
    Tsai-Turton M; Santillan A; Lu D; Bristow RE; Chan KC; Shih IeM; Roden RB
    Gynecol Oncol; 2009 Jul; 114(1):12-7. PubMed ID: 19398128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis.
    Høgdall EV; Høgdall CK; Blaakaer J; Heegaard NH; Glud E; Christensen L; Bock JE; Nørgaard-Pedersen B; Wiik A; Kjaer SK
    APMIS; 2002 Aug; 110(7-8):545-53. PubMed ID: 12390412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of candidate serologic markers for type I and type II ovarian cancer.
    Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
    Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells.
    Vogl FD; Stickeler E; Weyermann M; Köhler T; Grill HJ; Negri G; Kreienberg R; Runnebaum IB
    Oncology; 1999 Nov; 57(4):324-9. PubMed ID: 10575320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer.
    Häfner N; Nicolaus K; Weiss S; Frey M; Diebolder H; Rengsberger M; Dürst M; Runnebaum IB
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1207-10. PubMed ID: 23576021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel algorithm to improve specificity in ovarian cancer detection.
    Arjomandi A; Delanoy ML; Walker RP; Binder SR
    Cancer Treat Res Commun; 2018; 15():32-35. PubMed ID: 30207285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass.
    Vogl FD; Frey M; Kreienberg R; Runnebaum IB
    Br J Cancer; 2000 Nov; 83(10):1338-43. PubMed ID: 11044359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer.
    Wilson AL; Moffitt LR; Duffield N; Rainczuk A; Jobling TW; Plebanski M; Stephens AN
    Cancer Epidemiol Biomarkers Prev; 2018 Feb; 27(2):183-192. PubMed ID: 29141850
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers.
    Katchman BA; Barderas R; Alam R; Chowell D; Field MS; Esserman LJ; Wallstrom G; LaBaer J; Cramer DW; Hollingsworth MA; Anderson KS
    Proteomics Clin Appl; 2016 Jul; 10(7):720-31. PubMed ID: 27121307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.
    Abendstein B; Marth C; Müller-Holzner E; Widschwendter M; Daxenbichler G; Zeimet AG
    Cancer; 2000 Mar; 88(6):1432-7. PubMed ID: 10717627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
    Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
    J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.
    Kaaks R; Fortner RT; Hüsing A; Barrdahl M; Hopper M; Johnson T; Tjønneland A; Hansen L; Overvad K; Fournier A; Boutron-Ruault MC; Kvaskoff M; Dossus L; Johansson M; Boeing H; Trichopoulou A; Benetou V; La Vecchia C; Sieri S; Mattiello A; Palli D; Tumino R; Matullo G; Onland-Moret NC; Gram IT; Weiderpass E; Sánchez MJ; Navarro Sanchez C; Duell EJ; Ardanaz E; Larranaga N; Lundin E; Idahl A; Jirström K; Nodin B; Travis RC; Riboli E; Merritt M; Aune D; Terry K; Cramer DW; Anderson KS
    Int J Cancer; 2018 Aug; 143(3):515-526. PubMed ID: 29473162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
    Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
    Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.
    Fortner RT; Damms-Machado A; Kaaks R
    Gynecol Oncol; 2017 Nov; 147(2):465-480. PubMed ID: 28800944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
    Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
    Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid, accurate and robust particle-based assay for the simultaneous screening of plasma samples for the presence of five different anti-cytokine autoantibodies.
    Guldager DKR; von Stemann JH; Larsen R; Bay JT; Galle PS; Svenson M; Ullum H; Hansen MB
    J Immunol Methods; 2015 Oct; 425():62-68. PubMed ID: 26080061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.